Immune Studies of Peripheral Blood From Patients With Malignant Disease Gastrointestinal Tract
- Quantify T cells specific for tumor peptides (carcinoembryonic antigen and MUC1) from
the peripheral blood of patients with colon cancer.
OUTLINE: This is an open-label study.
Patients undergo blood collection at time of follow-up, surgery, thoracentesis,
paracentesis, or leukapheresis (≤ 5 times per year). Blood is analyzed for tumor peptides
(carcinoembryonic antigen and MUC1), circulating cytokines, and lymphocyte response by
ELISA, ELISPOT, or intracellular flow.
PROJECTED ACCRUAL: A total of 140 patients will be accrued for this study.
Observational Model: Case-Only, Time Perspective: Prospective
Quantitation of T cells specific for tumor peptides (carcinoembryonic antigen and MUC1)
Michael Demeure, MD
University of Arizona
United States: Food and Drug Administration
|Arizona Cancer Center at University of Arizona Health Sciences Center||Tucson, Arizona 85724|